Sulfated glycosaminoglycan (sGAG) mimetic that targets soluble amyloid β (Aβ) and maintains Aβ in a non-fibrillar form. Decreases Aβ42-induced neuronal death and inhibits amyloid deposition in vitro. Decreases brain amyloid plaque load by 30%, increases tau polymerization and is brain penetrant. Also a GABA analog that protects against the convulsant and cytotoxic activity of kainic acid in vivo.